Abstract 5647: GS24-B057, a potential best-in-class Nectin-4- and Trop-2-directed bispecific ADC, for the treatment of urothelial carcinoma and other solid tumors.

癌症研究 内化 体内 医学 细胞毒性 膀胱癌 体外 癌症 旁观者效应 细胞 流式细胞术 癌细胞 癌 靶向治疗 细胞凋亡 细胞培养 移行细胞癌 乳腺癌 药理学 体外毒理学 尿路上皮癌 细胞周期 肿瘤科 肺癌 药代动力学 免疫疗法 化学 药敏试验 肿瘤微环境 化疗 拓扑异构酶抑制剂 前列腺癌
作者
M Y Li,Fu Li,Qiuru Che,Xiaojing Huang,Dongxia Chu,Qiyang Zhang,Nan Li,Qingjuan Ma,Weiming He,Wenqiang Zhai,Yihui Lin,Xiaozhen Wang,Fanglong Yang,Siqing Wang,Lei Jin,John L. Xu
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:86 (7_Supplement): 5647-5647
标识
DOI:10.1158/1538-7445.am2026-5647
摘要

Abstract Background: Nectin-4 and Trop-2 are transmembrane proteins commonly co-overexpressed in various solid tumors and associated with tumor progression. ADCs targeting Nectin-4 or Trop-2 have shown promising therapeutic potential in urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). Notably, the combination of Padcev™ (a Nectin-4-directed ADC; also referred to as EV) and Trodelvy™ (a Trop-2-directed ADC; also referred to as SG) as second-line therapy for metastatic UC has demonstrated significantly improved efficacy, with the overall response rate (ORR) reaching 70%. However, the safety profile of this combination remains to be a concern, with ≥Grade 3 treatment-emergent adverse events (TEAEs) occurring in 78% of patients. To maintain clinical efficacy while minimizing toxicity, we developed GS24-B057, a dual Nectin-4- and Trop-2-targeting ADC with a drug-to-antibody ratio (DAR) of 6, integrating an optimally engineered bispecific antibody, a tailored topoisomerase I inhibitor payload, and site-specific conjugation. Materials and Methods: The in vitro tumor cell binding activity of GS24-B057 was assessed by flow cytometry. For internalization analysis, Nectin-4- and Trop-2-expressing cells were incubated with pHrodo-conjugated ADC, followed by fluorescence intensity quantification. Cytotoxicity and bystander killing effect were assessed in a Cell Titer-Glo assay and in a luciferase assay, respectively. The in vivo anti-tumor efficacy of GS24-B057 was systematically examined in mouse models bearing human cancer cell line-derived xenografts (CDX) and patient-derived xenografts (PDX). Pharmacokinetics was studied in cynomolgus monkeys. Results: In preclinical studies, GS24-B057 exhibited significantly stronger in vitro cell binding and internalization than the EV and SG combination, as well as robust direct cytotoxicity and bystander killing effect in tumor cell lines. GS24-B057 demonstrated potent anti-tumor activity across multiple CDX and PDX models of human cancer, including UC, TNBC, and NSCLC, with superior efficacy versus EV, SG, and SKB264 as single agent, and comparable efficacy to the EV and SG combination but at a lower dose level and administration frequency. Furthermore, GS24-B057 featured a favorable pharmacokinetic profile in cynomolgus monkeys. Conclusion: These data suggest the potential of GS24-B057 as an effective therapeutic option for patients with UC and other solid tumors and support its further evaluation in IND-enabling studies. Citation Format: Meihan Li, Fu Li, Qiuru Che, Xiaojing Huang, Dongxia Chu, Qiyang Zhang, Nan Li, Qingjuan Ma, Weiming He, Wenqiang Zhai, Yihui Lin, Xiaozhen Wang, Fanglong Yang, Siqing Wang, Lei Jin, John L. Xu. GS24-B057, a potential best-in-class Nectin-4- and Trop-2-directed bispecific ADC, for the treatment of urothelial carcinoma and other solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5647.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XS_QI发布了新的文献求助10
刚刚
还有早安完成签到,获得积分10
刚刚
安详的夜春完成签到,获得积分10
刚刚
小鱼干完成签到,获得积分10
刚刚
自由的王发布了新的文献求助10
1秒前
开朗紫发布了新的文献求助10
1秒前
叶95完成签到,获得积分10
2秒前
2秒前
3秒前
3秒前
Maestro_S的应助被小鱼干采纳,获得10
4秒前
4秒前
吕锴岐完成签到 ,获得积分10
5秒前
huang完成签到 ,获得积分10
5秒前
5秒前
zjjcug完成签到,获得积分10
5秒前
苦昼短完成签到 ,获得积分10
5秒前
zzl完成签到,获得积分10
5秒前
大个的应助被小青采纳,获得10
6秒前
anqi6688完成签到,获得积分10
6秒前
Zzha10完成签到,获得积分10
6秒前
CarryLJR发布了新的文献求助10
6秒前
充电宝的应助被生而追梦不止采纳,获得10
7秒前
张伟的应助被漫漫采纳,获得10
8秒前
9秒前
9秒前
天才发布了新的文献求助10
10秒前
11秒前
衣锦夜行完成签到,获得积分10
13秒前
完美世界的应助被是小鱼采纳,获得10
13秒前
汉堡包的应助被11NING采纳,获得10
13秒前
hanks完成签到,获得积分10
14秒前
Largequail完成签到,获得积分10
15秒前
啦啦啦发布了新的文献求助10
15秒前
衣锦夜行发布了新的文献求助10
17秒前
李爱国的应助被乐观阑悦采纳,获得10
17秒前
李健的应助被合适的咖啡采纳,获得10
17秒前
Savananh_Xie发布了新的文献求助10
17秒前
啦啦啦啦啦完成签到 ,获得积分10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568